You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

First dose completed in phase 1 cannabinoid study

Oxford Cannabinoid Technologies Holdings (OCTP) has announced that the first-in-human dose of its drug candidate, OCT461201, has been successfully administered.